{"name":"Pacira Pharmaceuticals, Inc","slug":"pacira-pharmaceuticals-inc","ticker":"","exchange":"","domain":"pacira.com","description":"","hq":"Parsippany-Troy Hills","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"immunology","drugs":[{"name":"Exparel TAP + multi-modal pain regimen","genericName":"Exparel TAP + multi-modal pain regimen","slug":"exparel-tap-multi-modal-pain-regimen","indication":"Infiltration anesthesia and nerve block in surgical procedures","status":"marketed"},{"name":"Bupivacaine SNB","genericName":"Bupivacaine SNB","slug":"bupivacaine-snb","indication":"Local anesthesia for infiltration, nerve block, and regional anesthesia procedures","status":"marketed"},{"name":"EXPAREL and bupivacaine HCl","genericName":"EXPAREL and bupivacaine HCl","slug":"exparel-and-bupivacaine-hcl","indication":"Infiltration anesthesia and nerve block in adults for surgical anesthesia and postoperative analgesia","status":"marketed"},{"name":"Exparel + Bupivacaine","genericName":"Exparel + Bupivacaine","slug":"exparel-bupivacaine","indication":"Infiltration anesthesia for surgical anesthesia","status":"marketed"},{"name":"Exparel Injectable Product","genericName":"Exparel Injectable Product","slug":"exparel-injectable-product","indication":"Infiltration anesthesia and nerve block in adults","status":"marketed"},{"name":"Infiltration - EXPAREL","genericName":"Infiltration - EXPAREL","slug":"infiltration-exparel","indication":"Infiltration anesthesia for surgical procedures","status":"marketed"},{"name":"Instillation - EXPAREL","genericName":"Instillation - EXPAREL","slug":"instillation-exparel","indication":"Infiltration anesthesia for post-operative analgesia in surgical patients","status":"marketed"},{"name":"On-Q Pain Ball","genericName":"On-Q Pain Ball","slug":"on-q-pain-ball","indication":"Post-operative pain management following surgical procedures","status":"marketed"},{"name":"TCA IR 40","genericName":"TCA IR 40","slug":"tca-ir-40","indication":"Postoperative pain management","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"EXPAREL Infiltration","genericName":"EXPAREL Infiltration","slug":"exparel-infiltration","indication":"Other","status":"marketed"},{"name":"IV morphine sulfate or Sponsor-approved equivalent","genericName":"IV morphine sulfate or Sponsor-approved equivalent","slug":"iv-morphine-sulfate-or-sponsor-approved-equivalent","indication":"Other","status":"marketed"},{"name":"Bupivacaine FNB","genericName":"Bupivacaine FNB","slug":"bupivacaine-fnb","indication":"Infiltration anesthesia and nerve block in adults","status":"marketed"},{"name":"EXPAREL 20 mL","genericName":"EXPAREL 20 mL","slug":"exparel-20-ml","indication":"Other","status":"marketed"},{"name":"EXPAREL 40 mL","genericName":"EXPAREL 40 mL","slug":"exparel-40-ml","indication":"Other","status":"marketed"},{"name":"FX201","genericName":"FX201","slug":"fx201","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"EXPAREL Infiltration","genericName":"EXPAREL Infiltration","slug":"exparel-infiltration","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Exparel TAP + multi-modal pain regimen","genericName":"Exparel TAP + multi-modal pain regimen","slug":"exparel-tap-multi-modal-pain-regimen","phase":"marketed","mechanism":"Exparel is a liposomal bupivacaine formulation that provides prolonged local anesthesia when infiltrated into surgical sites, often combined with other pain management modalities to reduce opioid requirements.","indications":["Infiltration anesthesia and nerve block in surgical procedures","Transversus abdominis plane (TAP) block for abdominal surgery pain management"],"catalyst":""},{"name":"IV morphine sulfate or Sponsor-approved equivalent","genericName":"IV morphine sulfate or Sponsor-approved equivalent","slug":"iv-morphine-sulfate-or-sponsor-approved-equivalent","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bupivacaine FNB","genericName":"Bupivacaine FNB","slug":"bupivacaine-fnb","phase":"marketed","mechanism":"Bupivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and conduction of nerve impulses.","indications":["Infiltration anesthesia and nerve block in adults","Interscalene brachial plexus nerve block for shoulder surgery","Femoral nerve block for knee surgery","Sciatic nerve block for lower extremity surgery"],"catalyst":""},{"name":"Bupivacaine SNB","genericName":"Bupivacaine SNB","slug":"bupivacaine-snb","phase":"marketed","mechanism":"Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.","indications":["Local anesthesia for infiltration, nerve block, and regional anesthesia procedures","Postoperative pain management via nerve block"],"catalyst":""},{"name":"EXPAREL 20 mL","genericName":"EXPAREL 20 mL","slug":"exparel-20-ml","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EXPAREL 40 mL","genericName":"EXPAREL 40 mL","slug":"exparel-40-ml","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EXPAREL and bupivacaine HCl","genericName":"EXPAREL and bupivacaine HCl","slug":"exparel-and-bupivacaine-hcl","phase":"marketed","mechanism":"EXPAREL is a liposomal formulation of bupivacaine that provides prolonged local anesthesia by slowly releasing bupivacaine from lipid vesicles to block sodium channels in nerve fibers.","indications":["Infiltration anesthesia and nerve block in adults for surgical anesthesia and postoperative analgesia","Interscalene brachial plexus nerve block for postoperative analgesia"],"catalyst":""},{"name":"Exparel + Bupivacaine","genericName":"Exparel + Bupivacaine","slug":"exparel-bupivacaine","phase":"marketed","mechanism":"Exparel is a liposomal formulation of bupivacaine that provides prolonged local anesthetic effect by slowly releasing bupivacaine from lipid vesicles at the injection site.","indications":["Infiltration anesthesia for surgical anesthesia","Interscalene brachial plexus nerve block","Transversus abdominis plane (TAP) block","Postsurgical analgesia"],"catalyst":""},{"name":"Exparel Injectable Product","genericName":"Exparel Injectable Product","slug":"exparel-injectable-product","phase":"marketed","mechanism":"Exparel is a liposomal formulation of bupivacaine that provides prolonged local anesthesia by slowly releasing the anesthetic agent over an extended period.","indications":["Infiltration anesthesia and nerve block in adults","Postsurgical analgesia"],"catalyst":""},{"name":"FX201","genericName":"FX201","slug":"fx201","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Infiltration - EXPAREL","genericName":"Infiltration - EXPAREL","slug":"infiltration-exparel","phase":"marketed","mechanism":"EXPAREL is a long-acting local anesthetic that blocks sodium channels in nerve fibers to provide prolonged infiltration anesthesia and post-operative pain relief.","indications":["Infiltration anesthesia for surgical procedures","Post-operative analgesia following surgery"],"catalyst":""},{"name":"Instillation - EXPAREL","genericName":"Instillation - EXPAREL","slug":"instillation-exparel","phase":"marketed","mechanism":"EXPAREL is a long-acting local anesthetic that blocks sodium channels in nerve fibers to provide prolonged post-operative pain relief.","indications":["Infiltration anesthesia for post-operative analgesia in surgical patients","Interscalene brachial plexus nerve block for post-operative pain management"],"catalyst":""},{"name":"On-Q Pain Ball","genericName":"On-Q Pain Ball","slug":"on-q-pain-ball","phase":"marketed","mechanism":"On-Q Pain Ball is a elastomeric infusion pump that delivers local anesthetic (bupivacaine) continuously to surgical sites for post-operative pain management.","indications":["Post-operative pain management following surgical procedures","Infiltration anesthesia for wound pain control"],"catalyst":""},{"name":"TCA IR 40","genericName":"TCA IR 40","slug":"tca-ir-40","phase":"phase_3","mechanism":"TCA IR 40 is a local anesthetic that works by blocking nerve signals.","indications":["Postoperative pain management"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOYWt4SW4xTnA3QUtvdTdZTHFfSXh0bHNlckFhc0FJMGFucnByNFFSNFV6bzdONEtZNDB0ODRTLVdoN2tPUTktMm1zRGl4X01DSHctWnJXNVZSUDJqWmM1aGkwc1ZkM3F6ZVlTa0xvVTA2ellmY1d1M2ZGdEUtRXdqVFcyc1J6c25JYVhlejFpSzFlLUNDN1hV?oc=5","date":"2026-04-07","type":"pipeline","source":"pharmacytimes.com","summary":"Re-adding EXPAREL to Formulary: The Pharmacist Perspective - pharmacytimes.com","headline":"Re-adding EXPAREL to Formulary: The Pharmacist Perspective","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOQ1J4c2ZjcGtWcHBpR0xLckljLWF3eFpDRVBQV3RDbUVIbjdCMXBZelQ3U2x3c0FPMmdrX1VueC1TUFNTbXZNbU4xdTBwaFptT3hGaHJoU1ktV1dWMWhmeC15T29UWXZPaEJFRGI0cTlic0tUbFZwYUZjM3Q5WkpNaEJiYTlTbHY3bEU1X2FTMEtELTNESFVXQlRrX0paWEJacU5RWUZ2ejBIVGo4M2FoVUxvTmNZRlhIRF9kTw?oc=5","date":"2026-02-03","type":"earnings","source":"TradingView","summary":"5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView","headline":"5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxNa29wNHlUcHhYNFZaa083Yy1UV09sak9VcWsyOV9Dd2xobHZkSFZPNWpsc2NGdFhESzZBcHlKaGNXLWw2b2hZX3pZcUswRUlydFJzTEMzeFdDUmRnUVNfMG5LM0t3MWo5TVRHQlVOMzE4UEZFb2RIbkV0VE5EWExmZG9haW15Zl90R0F5TzY5cVpkbWNxMkdNMF9tQ0N1NDNIQWgxc3d1UHJvOXhkajQtSHJoZFdXOXRsNFZjajZUaldWal9uQUdXb3FDZWNHVFY0Njlxa0ttLTVtYlc5SHBmUEZNX3h5NlVoTnRBbV95V0RPT2psMlZEYlVrdlRvRVBPejdmejJKQVQzVmlMOEtDNzhB?oc=5","date":"2025-11-26","type":"patent","source":"GlobeNewswire","summary":"Pacira BioSciences Files EXPAREL® Patent Infringement - GlobeNewswire","headline":"Pacira BioSciences Files EXPAREL® Patent Infringement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOdkFSbk5VbUdXQ21pWFJUTHdCUFVqNWVJUWhaV3k4ckFYV2pLYm4xc0gxcmp5eENBc1ZrWHJPQ0dHaGwxX2F4WkVTWGc3ZVJKdjRUR21sSzJxdlMxc21VUktWMkZXWllNMXR3OWEtd2ExQ3BCV245UW9nbUxqdTlnYUUyQjQ1OTRsT2pMdjh2Vmt2UkI4SlZmbEVINlVfWl9GcXhkcmpCRld2U0liVXVONkE5UnhfMlJKaXRBakloU3V5N2J5Q3c?oc=5","date":"2025-07-11","type":"pipeline","source":"fiercepharma.com","summary":"Non-opioid pain drug maker Pacira lays off 71 in California, retires facility in manufacturing upgrade - fiercepharma.com","headline":"Non-opioid pain drug maker Pacira lays off 71 in California, retires facility in manufacturing upgrade","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE94RW1ObTBnTzNvMnduS2M3cTVKUVh0LWFpaWxYOVpfS1E0T1ltb21vUGVFa3Z2YTFaaGtfZjNqSlVQeHdNemR5ZHVaMVdRdjFzYVFv?oc=5","date":"2025-07-11","type":"pipeline","source":"FirstWord Pharma","summary":"Biotech layoff wave hits Karyopharm, Century and Pacira - FirstWord Pharma","headline":"Biotech layoff wave hits Karyopharm, Century and Pacira","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE85a0RYbXBYMWRfejB4UnlGT3hrMlB0NjFpUzUtdXlNbXF2MXczTVhPSU9PSjVFd1A0bE5WeE1na0dPY2NwRWUwRFRfZDdrUDh3eXFB?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"PCRX Stock Price, News & Analysis - Stock Titan","headline":"PCRX Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOYXJjeEg4d2lNeFF1c0F6bm03Y1EyVUozX0N2Y1owUFFUdGxfS0xXejRqUmZMbkZBdUFQTE82R2plQks4VXZOa1B1VXU5UVR5c3l0RVJoQ0xhal8zd2hHcVhBeUZicWpMRmlXV0Y5MUF3cm54cHVFRDRtamlQREREMDBFSVJlWHdUcmlsSzVpVW1GYjY4Vi0wak9Mc1NRMkVqRzVvOGptbjVfa0tLNVEzZVpkTQ?oc=5","date":"2025-04-09","type":"regulatory","source":"seekingalpha.com","summary":"Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act - seekingalpha.com","headline":"Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPeUJpOEtfQ0pEb2tteExOV0xMZ1ZVWk5WVjFzSzlhN3Z3QTdLOHEwaXBTcTZ5NEFjZFRLSGJkcGZFNkh2Zzl2MkhrenpGYXlsRlJpSWg3ZjdIQWdtRDk2ZE9NeWM1R2c5WTRlTng0YUVjbGsyd2h4UUVHZDI0bXR0Z01ZWVkxZ1A5ZnVoU01jekdneFd3YjF5QW530gFWQVVfeXFMTTJqZ2dUMEhnUlBTQV9KQ0JKS2FXQVdaNlJyc25ad09sVElQYWJ0eTVfY1FtWDZEVmxDUkpPa0NCMmlzamp5YnQyRUtNOWg3ZldReUpid0E?oc=5","date":"2023-11-03","type":"pipeline","source":"Law360","summary":"Pacira Hits Rivals With False Ad Suits Over Pain Drugs - Law360","headline":"Pacira Hits Rivals With False Ad Suits Over Pain Drugs - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNMUxreVZkWS1jbW1QY0NDdEc0SjVWSDN0dDlJVzhKVzVVcW5fanNJQmh2TURuWEVDeTNaNkl4TmlyaERJdVBVMGQ5WHBZc0l6WF93aDQyOWc5NXZObWFERVJfdlRHTHJmelhPSHNpUHhJOS05a1ZYMjlvVkMzbnd2T2Zad3pGTVdXNFZUWU5OZ1BQdVdJY0dpTUtTeTJFSURpeHpKVFhkTFVndw?oc=5","date":"2020-07-29","type":"pipeline","source":"NCDOJ (.gov)","summary":"Attorney General Josh Stein Reaches Settlement over Pharma Company Kickback Allegations - NCDOJ (.gov)","headline":"Attorney General Josh Stein Reaches Settlement over Pharma Company Kickback Allegations - NCDOJ (.gov)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOemZYd0NsNHloaVlMWTctZnZ5dXJHdC00eEVSc19nblo1MGcxM3RXaFB1Y0hWS3BjZHBPTDZ4NElSVTRVdW0xTGptQWJVWC1qZGtNeHZVdFh1NlFKckZxTVdBbWdsM1htVTQ3MXRicGVtSFMxY29qSW1VWExnQlhUM2ZiXzRLclgtODYwbV9OY2phMHhXRFE?oc=5","date":"2019-01-06","type":"pipeline","source":"CT Mirror","summary":"Pharma cash flows to doctors for consultant work despite scrutiny - CT Mirror","headline":"Pharma cash flows to doctors for consultant work despite scrutiny","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQeUctbDJ1UGpMaFlVRHd6SFZ5VFZBOW1VSVowVVBqMjZDcnlsMExWckhmN3p0M1FfUGJfZFdockZncDZIek52dkZPamlXTTFuOUQycVdENDNva3hBYms0ZDVIVkEtSHI0NU4xMUliQXl4QjFmZVJBdTNrV2lIS2JoOGJBUktyd2ZIaHhYNEp2LUluTzQtN2t5b01KYUc2aTZ2U29JOFlTejZsM3VhUFQ3NHhxZ3Z3dV9ETG9wMGZDS2hEZGFJeXVaUW4yOXQ3V25HZ1E?oc=5","date":"2017-07-17","type":"pipeline","source":"NJBIZ","summary":"Opioid fighter Pacira's Stack, longtime pharma exec, has very personal reason to develop a non-addictive pain medication - NJBIZ","headline":"Opioid fighter Pacira's Stack, longtime pharma exec, has very personal reason to develop a non-addictive pain medication","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2016-03-05","type":"regulatory","source":"Fox Business","summary":"Pacira Pharma skids as FDA refuses to grant new clearance for post-surgery pain drug Exparel - Fox Business","headline":"Pacira Pharma skids as FDA refuses to grant new clearance for post-surgery pain drug Exparel","sentiment":"negative"}],"patents":[],"drugCount":15,"phaseCounts":{"marketed":13,"phase_1":1,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}